Mark Potter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mark Potter has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Anjelique Sawh-Gopal
The Herbert Wertheim UF Scripps Institute for Biomedical Technology and Innovation, Jupiter, USA
1 shared publication - Antonette Bennett
Department of Biochemistry and Molecular Biology, University of Florida
1 shared publication - James B. Heidings
Department of Pharmacology and Therapeutics, College of Medicine, University of Florida, Gainesville, Florida, United States of America
1 shared publication - Jane Hsi
Department of Biochemistry & Molecular Biology, University of Florida, Gainesville, FL 32610, USA
1 shared publication - Jonathan E. Bird
Department of Pharmacology and Therapeutics, University of Florida, Gainesville, USA
1 shared publication - Juha T. Huiskonen
Institute of Biotechnology, Helsinki Institute of Life Science HiLIFE, University of Helsinki, Helsinki, Finland
1 shared publication
Latest Publications
- Open Access
AAV2 Crosslinks Actin Filaments: Implications for AAV Gene Therapy Vector Design
Adeno-associated virus (AAV) capsids are important gene therapy vectors, allowing for the one-time treatment of monogenetic disorders, with durable gene expression lasting for years. However, despite the clinical success of AAV usage, low transduction efficiencies require high dosage to achieve therapeutic efficacy, resulting in prohibitive costs and rare, but life-threatening immune responses. One key knowledge gap is how the capsids traffic to the nucleus following endocytosis. Here, we identify a direct interaction between AAV2 and actin filaments. Our results show that AAV2 bundles multiple actin filaments in a highly periodic hexagonal lattice. Therefore, we propose that AAV2 is the founding member of a new class of actin binding proteins, the actin bundling viruses (ABVs). Using cryogenic electron microscopy, we determined the structure of AAV2-actin filaments, identified the interaction interfaces, and engineered capsid variants that no longer bundle actin. Together, our results suggest that the AAV2-actin interaction may be responsible for trapping capsids and mediating peri-nuclear accumulation. Overall, this interaction expands the current understanding of AAV2 biology and offers new directions for capsid engineering.
Open AccessAAV2 Crosslinks Actin Filaments: Implications for AAV Gene Therapy Vector Design
Adeno-associated virus (AAV) capsids are important gene therapy vectors, allowing for the one-time treatment of monogenetic disorders, with durable gene expression lasting for years. However, despite the clinical success of AAV usage, low transduction efficiencies require high dosage to achieve therapeutic efficacy, resulting in prohibitive costs and rare, but life-threatening immune responses. One key knowledge gap is how the capsids traffic to the nucleus following endocytosis. Here, we identify a direct interaction between AAV2 and actin filaments. Our results show that AAV2 bundles multiple actin filaments in a highly periodic hexagonal lattice. Therefore, we propose that AAV2 is the founding member of a new class of actin binding proteins, the actin bundling viruses (ABVs). Using cryogenic electron microscopy, we determined the structure of AAV2-actin filaments, identified the interaction interfaces, and engineered capsid variants that no longer bundle actin. Together, our results suggest that the AAV2-actin interaction may be responsible for trapping capsids and mediating peri-nuclear accumulation. Overall, this interaction expands the current understanding of AAV2 biology and offers new directions for capsid engineering.